Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 24, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 24, 2025 -- Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder cancer (MIBC), according to a study published online Jan. 14 in the Journal of Clinical Oncology.

Richard T. Bryan, Ph.D., from the University of Birmingham in the United Kingdom, and colleagues conducted a prospective open-label randomized study within 17 U.K. hospitals involving patients with suspected new bladder cancer who were randomly assigned to transurethral resection of bladder tumor (TURBT)-staged or mpMRI-staged care to examine whether treatment could be expedited for MIBC with mpMRI.

A total of 638 patients were screened between May 31, 2018, and Dec. 31, 2021, and 143 were randomly assigned to TURBT or initial mpMRI (72 and 71, respectively). Thirty-six of 39 participants with suspected MIBC underwent mpMRI for feasibility. The researchers found that for participants with MIBC, the median TTCT was significantly shorter with initial mpMRI (53 days versus 98 days for TURBT). No detriment was seen for participants with non-MIBC (median TTCT, 17 days for mpMRI versus 14 days for TURBT). There were no reports of serious adverse events.

"Incorporating mpMRI ahead of TURBT into the standard pathway was beneficial for all patients with suspected MIBC. TURBT could be avoided in a proportion of these patients," the authors write. "This approach can improve decision-making and accelerate time to treatment."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords